GRIN powers HNF’s patient-centered research and drug discovery initiatives.

by | Apr 15, 2020 | 2 comments

The Global Registry for Inherited Neuropathies (GRIN) powers the Hereditary Neuropathy Foundation’s patient-centered research and drug discovery initiatives. Leading Charcot-Marie-Tooth advocacy organization’s innovative platform plays a critical role in its mission.

Our registry, GRIN, has been central to our patient centered research initiatives for over 6 years. The ability to have real-time access to important patient reported natural history data has been a game changer for HNF’s research, industry and academic partners. Originally hosted using 3rd party software, in 2019 HNF migrated GRIN onto our own IRB approved, HIPAA compliant platform. Built to our own specifications, GRIN allows us to quickly analyze data to uncover insightful correlations between genotypes, phenotypes, comorbidities and other important patient data.

GRIN has played a critical role in identifying important issues related to the CMT patient experience, revealing new areas to explore and research. When pain was noted by 65% of patients with inherited neuropathies, HNF quickly sprang into action, hosting a dedicated summit on patient pain in 2017, as well as advocating for pain scales to be considered as a secondary endpoint for clinical trials. “Without real time access to this critical data point, we wouldn’t have been able to demonstrate the importance of this issue to our industry and research partners,” says Joy Aldrich, HNF’s Patient Advocacy Director. “GRIN also helped us effectively convey the CMT patient’s disease experience for our Externally-led, Patient Focused Drug Discovery meeting with the FDA in 2018.”

GRIN has also facilitated recruitment for the latest clinical trials by pinpointing ideal candidates with speed and accuracy. Future innovations for the platform include an interactive patient portal, the integration of de identified data with other partner consortiums, and the collection of longitudinal patient data. GRIN also supports the CMT&Me app, sponsored by Pharnext, by identifying patients that are willing to participate in that important digital lifestyle study

To participate and accelerate research, join GRIN. www.hnf-cure.org/registry 

Contact: Allison Moore [email protected]

 

 

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Join the conversation

Leave a Comment

2 Comments

  1. Werner Walther

    I was prepared to fill in the GRIN regitry data.
    The form, however dropped me out and went back to the beginning.
    I feel, there is something wrong with entering data.

    Reply

Leave a Reply to Werner Walther Cancel reply

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news